Skip to Content

Genedata Provides Expressionist Platform to Eisai Research Institute

WALTHAM, Mass., January 17, 2008--Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced an agreement with the Eisai Research Institute (ERI) for the company’s Genedata Expressionist® biomarker discovery platform. Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system. With sophisticated high-throughput data processing and automated workflows for quality assessment, statistical analysis and interpretation functionalities, the platform provides a single-point-of-access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.

Jens Hoefkens, Managing Director of Genedata Inc., said, “We are very pleased to be working with the Eisai Research Institute in meeting its bio-IT infrastructure needs for biomarker validation. As the latest of an increasing series of Expressionist installations, we view the institute’s choice as further validation of Expressionist’s appeal to researchers seeking a common platform of tools and applications for biomarker identification with stringent quality control and open data sharing.”

Contact Genedata

Christiane Becker Public Relations Phone +41 61 697 7378 Fax +41 61 697 7244

Kurt Zingler Genedata Inc. Head of US Business Phone +1 650 246 3897 Fax +1 650 246 3887

Genedata AG specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The company offers expertise in research informatics combined with open and scalable computational solutions. Our product suites include Genedata Phylosopher® for integrating, structuring, and analyzing research data, Genedata Screener® for high throughput screening analysis, and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin-off from Novartis, Genedata is headquartered in Basel, Switzerland, and has branches in Munich (Germany), Konstanz (Germany), Boston (USA), San Francisco (USA), and Tokyo (Japan). The company is also represented in Taiwan and Singapore. For more information visit

Disclaimer: The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


Genedata AG - Maulbeerstrasse 46 - 4016 Basel - Switzerland - Tel. +41 61 697 6099 - Fax +41 61 697 7244 -

Posted: January 2008